Alzheimer's Hearing Explores Role Of Early Diagnostic Tools In Drug Trials
This article was originally published in The Gray Sheet
Executive Summary
FDA should allow broad use of biomarkers and imaging tools that can diagnose early-stage Alzheimer's disease to foster development of needed drug treatments, a consortium of pharmaceutical companies and health foundations said at a Dec. 9 hearing before the House Energy and Commerce Subcommittee on Health.
You may also be interested in...
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Research In Brief
Imaging self-referral scrutiny
Research In Brief
Imaging self-referral scrutiny